Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022

March 2022 | 60 pages | ID: C8BA58F34208EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48-72 hours

DelveInsight’s, “Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cutaneous T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cutaneous T-Cell Lymphoma Understanding

Cutaneous T-Cell Lymphoma: Overview

Cutaneous T-cell lymphoma (CTCL) is a rare type of blood cancer. It begins in a type of white blood cell called the T-lymphocyte (T-cell). T-cells help prevent infections and other diseases. As odd as it sounds, most T-cells are found in our skin. That’s because our skin is the first line of defense against disease. The surface of an adult’s skin contains about 20 billion T-cells. That’s nearly twice as many T-cells as found in other parts of the body. There are many types of CTCL. More than half the people who develop CTCL will have one of the following types: Mycosis fungoides or Sйzary syndrome. Mycosis fungoides is the most common type of CTCL. This type tends to worsen very slowly. It can stay in its earliest stage, which often looks like rash, for years. In this stage, the cancer is often difficult to diagnose because it tends to looks like eczema or psoriasis. These conditions are much more common than CTCL. Sйzary syndrome is more aggressive. It can also look like eczema. Some people develop red and swollen skin over much of their body. Their skin may feel hot, sore, and extremely itchy. Because CTCL is rare and often looks like eczema or another common skin disease, it can take time to get the diagnosis. Some people who have CTCL are referred to a dermatologist because it’s thought that they have a stubborn case of eczema or psoriasis.

'Cutaneous T-Cell Lymphoma - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cutaneous T-Cell Lymphoma pipeline landscape is provided which includes the disease overview and Cutaneous T-Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Cutaneous T-Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cutaneous T-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cutaneous T-Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Cutaneous T-Cell Lymphoma.

Cutaneous T-Cell Lymphoma Emerging Drugs Chapters

This segment of the Cutaneous T-Cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cutaneous T-Cell Lymphoma Emerging Drugs

• SGX301: Soligenix

SGX301 is a novel first-in-class photodynamic therapy utilizing safe, visible light for activation. The active ingredient in SGX301 is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions, is taken up by the malignant T-cells, and then activated by fluorescent light 16 to 24 hours later. Currently, it is in the Phase III stage of clinical trial evaluation to treat Cutaneous T-Cell Lymphoma

• WP1220: Moleculin Biotech

WP1220 is a STAT3 transcription factor inhibitor being developed by Moleculin Biotech to treat CTCL. Preclinical research in multiple cutaneous T-cell lymphoma (“CTCL”) cell lines has suggested that WP1220 may effectively inhibit CTCL. Based on this data, the company collaborated with a Polish drug development company that has received Polish government grant money to develop WP1220 in Poland for the topical treatment of early-stage CTCL patients. CTCL is a potentially deadly form of skin cancer for which there are limited treatment options.

• Lacutamab : Innate Pharma

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages. KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular, Sйzary syndrome.

• BNZ-1: Bioniz

BNZ-1 is a selective inhibitor of three members of the IL-2 family: IL-2, IL-9, and IL-15. The profile of BNZ-1 is promising as a long-term therapy capable of transforming the standard of care in CTCL as data implicates the dysregulation of IL-2/IL-9/IL-15 as responsible for disease pathology. Bioniz conducted a Phase 1/2 study in CTCL, in which BNZ-1 exhibited a substantial improvement in safety and efficacy relative to standard of care. BNZ-1 has orphan drug designation in US and EU.

• exoIL 12: Codiak BioSciences

exoIL-12 is designed to generate local and systemic anti-tumor activity without systemic drug exposure. Historically, preclinical and clinical studies of IL-12 have shown a potent anti-tumor immune-response as a single agent through activation of T cells and NK cells. While the biological rationale for IL-12 as a cancer treatment has been encouraging, its utility has been severely limited due to an inability to consistently retain IL-12 locally and manage potentially serious adverse events caused by systemic exposure. In Codiak’s preclinical studies, the anti-tumor immune activity with exoIL-12 allowed for reduced IL-12 doses to achieve local and systemic tumor shrinkage and showed dose dependent injection-site retention and no measurable systemic exposure of IL-12.

Further product details are provided in the report……..

Cutaneous T-Cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Cutaneous T-Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cutaneous T-Cell Lymphoma

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-Cell Lymphoma. The companies which have their Cutaneous T-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Soligenix

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cutaneous T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cutaneous T-Cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cutaneous T-Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cutaneous T-Cell Lymphoma drugs.

Cutaneous T-Cell Lymphoma Report Insights

• Cutaneous T-Cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cutaneous T-Cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cutaneous T-Cell Lymphoma drugs?
• How many Cutaneous T-Cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cutaneous T-Cell Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cutaneous T-Cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cutaneous T-Cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Soligenix
• Merck Sharp & Dohme Corp
• Elorac
• Innate Pharma
• Viridian Therapeutics
• Sorrento Therapeutics
• Bio-Path Holdings
• Legend Biotech
• Genzada Pharmaceuticals
• VidacPharma
• Bioniz Therapeutics
• Otsuka Pharmaceutical
• Hoffmann-La Roche
• BioInvent International AB
• Scopus BioPharma
• Codiak BioSciences

Key Products

• SGX301
• BNZ-1
• Lacutamab
• ExoIL-12
• BP1002
• MRG-106
• BBI-3000
• WP1220
• Tucidinostat
• IPH4102
• Resiquimod

Contents

Introduction
Executive Summary
Cutaneous T-Cell Lymphoma: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Cutaneous T-Cell Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
  Comparative Analysis
SGX301: Soligenix
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Lacutamab: Innate Pharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
ExoIL-12: Codiak BioSciences
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  Comparative Analysis
Drugname: Company Name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Cutaneous T-Cell Lymphoma Key Companies
Cutaneous T-Cell Lymphoma Key Products
Cutaneous T-Cell Lymphoma- Unmet Needs
Cutaneous T-Cell Lymphoma- Market Drivers and Barriers
Cutaneous T-Cell Lymphoma- Future Perspectives and Conclusion
Cutaneous T-Cell Lymphoma Analyst Views
Cutaneous T-Cell Lymphoma Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cutaneous T-Cell Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cutaneous T-Cell Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products